Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Everest Medicines of Shanghai Closes $310 Million C Round for In-licensed Drugs

publication date: Jun 5, 2020

Everest Medicines, a Shanghai biopharma, announced a very large $310 million Series C round to support clinical trials of its in-licensed candidates. Everest was formed in 2015 with $50 million in initial backing led by China's C-Bridge Capital. At the time, C-Bridge described Everest as its incubator platform for bringing novel drugs to China. Ian Woo, president and CFO of Everest, previously said that Everest's plan was to acquire China rights to the best drugs of its partners, not assets that were sidelined during development. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here